Illinois Researchers Identify New Alzheimer's Therapy Target

A study links PSD-95 protein regulation to cognitive improvement in mouse models of neurological disorders.

Updated on Oct. 28, 2026 in Alzheimer’s

Close-up of clean glass laboratory vials and micropipettes on a white surface, representing medical research on neurological protein regulation. — University of Illinois researchers identified the PSD-95 protein as a potential therapeutic target to improve cognition and treat neurological disorders like Alzheimer's disease. AI Illustration. Upload story photo >

Live Poll

Do you believe current genetic research investment is effectively improving treatment options for rare neurological diseases?

University of Illinois researchers have identified the protein PSD-95 as a critical therapeutic target for treating conditions related to MEF2C deletions, such as Alzheimer's disease and epilepsy. By inhibiting this protein, scientists successfully restored cognitive function and reduced seizure activity in laboratory mice.

Why it matters

MEF2C deficiency leads to an excessive accumulation of PSD-95, as the body loses its ability to properly regulate the protein's degradation. Targeting this pathway offers a new approach to managing complex neurological disorders that currently lack effective treatments.

Researchers observed that PSD-95 levels consistently increase in the brains of mice suffering from MEF2C haploinsufficiency. The team successfully reduced these levels through both genetic knockdown and pharmacological intervention.

The players

University of Illinois

This major public research institution located in Champaign serves as the primary site for the scientific investigation into MEF2C-related disorders.

National Institutes of Health

This federal agency is the primary biomedical research arm of the U.S. government and provided the funding for the study.

The details

The team inhibited PSD-95 by breeding mice with a specific gene knockdown and by using a drug to block the interaction between PSD-95 and its receptor. These methods effectively mitigated seizures and improved behavioral outcomes related to social and object recognition.

October 27, 2026: Findings detailing the research were published in the journal Proceedings of the National Academy of Sciences.

The Big Picture

This study advances the MEF2C haploinsufficiency research field by providing a concrete method to restore cognitive function in mice. It shifts the focus from managing symptoms to addressing the specific molecular pathway responsible for neural degradation.

This discovery provides a new scientific pathway that could eventually lead to novel treatments for patients suffering from epilepsy or Alzheimer's. While the findings are currently limited to laboratory models, they offer a foundation for developing future pharmaceutical interventions.

The takeaway

Targeting protein accumulation in the brain may be the key to unlocking better treatments for severe neurological conditions. These findings underscore the importance of ongoing federal investment in basic neuroscience research.

What happens next

Researchers plan to investigate the role of the NMDA receptor in PSD-95 interactions and aim to identify additional drugs that can influence the PSD-95 neural signaling pathway.